Skip to content

Hyperthyroidism as a Potential Predictive of Worse Outcome of Renal Graft

Hyperthyroidism in the Immediate Post-kidney Transplantation Period: a Potential Predictive of Worse Outcome of Renal Graft

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06794203
Enrollment
100
Registered
2025-01-27
Start date
2022-09-02
Completion date
2025-07-01
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperthyroidism, Kidney Diseases, Kidney Transplant

Keywords

Hyperthyroidism, Kidney Diseases

Brief summary

The objectives of the study are: to research the association, if any, between the occurrence of thyroid function changes in the immediate post-transplant period and the prognosis of the transplant itself; identify any risk factors for the occurrence of thyroid disorders In the immediate post-transplant period.

Detailed description

Kidney transplant patients are by definition affected by MRC, regardless of eGFR. However, at the same time, several factors make them a unique category with distant characteristics from non-kidney transplant MRC patients. Immunosuppressant and corticosteroid therapy could affect a variety of systems, including the pituitary-thyroid-kidney axis. MTOR inhibitors, for example, would result in increased iodine uptake in TSH-stimulated thyrocytes. Corticosteroids, on the other hand, inhibit the conversion of T4 to T3 and inhibit the TSH production in a dose-dependent manner, and this activity could contribute to the low T3 syndrome that some sturi repot in the phase immediately following kidney transplantation. In addition, abrupt changes in the serum concentration of thyroid hormones in the immediate post kidney transplantation could be influenced by the stress surgery related to the surgery itself and by exposure to iodinated agents (antiseptics and iodinated contrast medium). The objectives of the study are: 1. To research the association, if any, between the occurrence of thyroid function changes in the immediate post-transplant period and the prognosis of the transplant itself in terms of: * Renal function three months after transplantation. * Medical complications in the post-transplant period (from surgery to patient discharge) * Patient survival at three months after transplantation. 2. Identify any risk factors for the occurrence of thyroid disorders In the immediate post-transplant period. During the past 5 years at the Transplant Center of the Nephrology OU, Dialysis, Transplantation of our hospital, 579 kidney transplants have been performed with an average of about 115 transplants per year. It is therefore estimated for our study a sample size of about 100 patients, given the need to meet the inclusion criteria.

Interventions

None listed

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Subjects transplanted at our Center; * Subjects whose 3-month follow-up is available; * Age ≥18 years; * Availability of clinical and laboratory data regarding thyroid function trends in the immediate post-transplant period (within 30 days after transplantation); * Subjects giving informed consent to participate.

Exclusion criteria

* None.

Design outcomes

Primary

MeasureTime frameDescription
Thyroid functionAt baseline, then 3-month follow-up after kidney transplantationTo research, if any, the alteration of thyroid function in the immediate post-transplant period
Renal functionAt 3-month follow-up after kidney transplantationInvestigating renal function three months after transplantation.
Medical complicationsBaseline (surgery), at 3-month follow-up after kidney transplantation, at patient dischargeInvestigate about medical complications in the post-transplant period
SurvivalAt 3-month follow-up after kidney transplantationPatient survival at three months after transplantation.

Countries

Italy

Contacts

Primary ContactGaetano La Manna, MD
gaetano.lamanna@unibo.it+39 051 214 4577

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026